A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration 

Nov 08 2025
Convention Center: Room 151, Level 1
12:30 PM - 2:00 PM

Description

Join our experts as they discuss practical aspects of integrating liver-directed therapy for the treatment of MASH. Listen as they discuss real-world successes and challenges with using THR-B agonists and GLP-1RAs. Catch up on the latest data on noninvasive testing and other treatments in late-stage development. 

Supported by: Madrigal Pharmaceuticals

Organized by: AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Link: 

Journey Maps

Objectives

  • Upon successful completion of this activity, participants should be better able to: Describe the mechanistic and clinical rationale for THR-b agonists as a means of treating MASLD/MASH
  • Evaluate the evidence on THR-b agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
  • Identify best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
  • Develop guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios